News

The company reported the successful completion of its 28-day rat toxicology. Results demonstrated an ample margin of safety with the dosing planned for the first-in-human study.

Partnership includes US profit share and co-promotion option for Epizyme. The strategic alliance in March 2011 aimed to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

Oral treatment can increase patient compliance in the estimated $15 billion US market. The company has filed a provisional patent application for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

The companies will develop novel drug candidates against multiple targets across different therapeutic areas.

Transaction creates new Nanohale subsidiary named Formycon GmbH.

The partners announced the selection of several novel agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

Completion of Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

The commercial partnership with Pioneer Pharma Co., Ltd., a Shanghai-based company that markets high-end pharmaceutical products into China, is for the commercialization of NeutroPhase in this territory. Under the terms of the agreement, NovaBay will receive an upfront payment of over $300,000.

Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.

The companies announced that they have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection.